Premium
Molindone: An indole derivative with antipsychotic activity
Author(s) -
Sugerman A. Arthur,
Herrmann Jane
Publication year - 1967
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196782261
Subject(s) - antipsychotic , euphoriant , psychology , atypical antipsychotic , extrapyramidal symptoms , dystonia , psychosis , medicine , psychiatry , schizophrenia (object oriented programming)
In the first clinical pharmacological trial of EN‐1733A, an oxygenated indole derivative not closely related to other antipsychotic drugs, it was given to 11 chronic schizophrenic men in doses increasing from 5 to 200 mg. daily. The maximum period of administration was 13 weeks. Independent global ratings of clinical change by 2 investigators showed some improvement in at least 7 patients. Behavioral rating scales showed most improvement in the second month of therapy, at a dose level of 50 to 125 mg. daily; especially notable were improvements in disorientation, thinking and perceptual distortion, schizophrenic disorganization, and social competence. Unusual euphoria was also observed. Improvement in appetite and gain in weight occurred late in the study. Side effects included an early marked drowsiness and moderate extrapyramidal effects, mainly of an akathisic kind, with occasional tremor and dystonia.